E-drug: Legal innovation from AstraZeneca? (cont'd)
---------------------------------------------
Dear Colleagues,
I am copying the message to the Evidence-Based-Health list. To my
knowledge, there have not been similar threats of legal action when
considering inclusions/exclusions in our Essential Drug List in
Colombia. The list is certainly the basis for reimbursement within the
system. Pressure and lobby may exist, but it may come in more
sophisticated (perhaps equally or more effective) ways.
The issue also raises another point, that of the legal and ethical
implications of those developing, implementing and following (or not!)
clinical practice guidelines (CPG), even those that are evidence-based.
I thought actions as that of Astra-Zeneca would not happen in a CPG
in a legally-minded society and high-stakes scenario as the US.
Sobering that it happened in Canada.
Regards,
Rodolfo J Dennis, MD MSc
Chairman of Medicine, Pontificia Universidad Javeriana
Bogot�, Colombia
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.